Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis

被引：2
|
作者：
Rabe, Klaus F. [1 ,2 ,3 ]
Martinez, Fernando J. [4 ]
Ferguson, Gary T. [5 ]
Wang, Chen [6 ]
Singh, Dave [7 ]
Wedzicha, Jadwiga A. [8 ]
Trivedi, Roopa [9 ]
St Rose, Earl [10 ]
Ballal, Shaila [10 ]
Mclaren, Julie [11 ]
Darken, Patrick [10 ]
Aurivillius, Magnus [12 ]
Reisner, Colin [10 ]
Dorinsky, Paul [9 ]
机构：
[1] LungenClin Grosshansdorf, Kiel, Germany
[2] Christian Albrechts Univ Kiel, Airway Res Ctr North, Kiel, Germany
[3] German Ctr Lung Res DZL, Kiel, Germany
[4] Weill Cornell Med, Joan & Sanford I Weill Dept Med, New York, NY USA
[5] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA
[6] China Japan Friendship Hosp, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China
[7] Univ Manchester, Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[8] Imperial Coll London, Natl Heart & Lung Inst, London, England
[9] AstraZeneca, Durham, NC USA
[10] AstraZeneca, Morristown, NJ USA
[11] AstraZeneca, Gaithersburg, MD USA
[12] AstraZeneca, Gothenburg, Sweden
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
D O I：
10.1183/13993003.congress-2020.984
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
984
引用
收藏
页数：3
相关论文
共 41 条
  • [1] Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
    Rabe, K. F.
    Martinez, F. J.
    Ferguson, G. T.
    Wang, C.
    Singh, D.
    Wedzicha, J.
    Trivedi, R.
    Rose, E.
    Ballal, S.
    McLaren, J.
    Darken, P.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    PNEUMOLOGIE, 2021, 75 : S12 - S12
  • [2] COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
    Martinez, Fernando J.
    Rabe, Klaus F.
    Ferguson, Gary T.
    Wang, Chen
    Singh, Dave
    Wedzicha, Jadwiga A.
    Trivedi, Roopa
    St Rose, Earl
    Ballal, Shaila
    Mclaren, Julie
    Darken, Patrick
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [3] Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
    Ferguson, Gary T.
    Rabe, Klaus F.
    Martinez, Fernando J.
    Wang, Chen
    Singh, Dave
    Wedzicha, Jadwiga A.
    Trivedi, Roopa
    St Rose, Earl
    Ballal, Shaila
    Mclaren, Julie
    Darken, Patrick
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [4] Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
    Ferguson, G. T.
    Rabe, K. F.
    Martinez, F. J.
    Wang, C.
    Singh, D.
    Wedzicha, J.
    Trivedi, R.
    Rose, E.
    Ballal, S.
    McLaren, J.
    Darken, P.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    PNEUMOLOGIE, 2021, 75 : S13 - S13
  • [5] Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS Trial
    Rabe, K. F.
    Martinez, F. J.
    Ferguson, G. T.
    Wang, C.
    Singh, D.
    Wedzicha, J. A.
    Trivedi, R.
    St Rose, E.
    Ballal, S.
    McLaren, J.
    Darken, P.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [6] Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis)
    Fabbri, Leonardo Michele
    Rabe, Klaus F.
    Martinez, Fernando J.
    Ferguson, Gary T.
    Wang, Chen
    Ichinose, Masakazu
    Bourne, Eric
    Ballal, Shaila
    Darken, Patrick
    Deangelis, Kiernan
    Aurivillius, Magnus
    Dorinsky, Paul
    Reisner, Colin
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [7] RATE OF SEVERE COPD EXACERBATIONS WITH BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMA-RATE DIHYDRATE METERED DOSE INHALER (BGF MDI) VERSUS DUAL THERAPIES: A POST-HOC SUBGROUP ANALYSIS OF THE ETHOS TRIAL
    Ferguson, G. T.
    Rabe, K. F.
    Martinez, F. J.
    Singh, D.
    Trivedi, R.
    Darken, P.
    Jenkins, M.
    Aurivillius, M.
    Dorinsky, P.
    THORAX, 2021, 76 : A16 - A16
  • [8] Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults
    Dorinsky, Paul
    Depetrillo, Paolo
    Deangelis, Kiernan
    Trivedi, Roopa
    Mo, Mindy
    Ballal, Shaila
    Gillen, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [9] COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
    Rabe, Klaus F.
    Martinez, Fernando J.
    Ferguson, Gary T.
    Singh, Dave
    Wedzicha, Jadwiga A.
    Jenkins, Martin
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    INTERNIST, 2021, 62 (SUPPL 2): : 181 - 181
  • [10] COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
    Rabe, K. F.
    Martinez, F. J.
    Ferguson, G. T.
    Singh, D.
    Wedzicha, J.
    Jenkins, M.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    PNEUMOLOGIE, 2021, 75 : S12 - S13
12345